Spiramycin-loaded maltodextrin nanoparticles as a promising treatment of toxoplasmosis on murine model.

Autor: Abdel-Wahab AA; Department of Clinical and Molecular Parasitology, National Liver Institute, Menoufia University, Menoufia, Egypt., Shafey DA; Department of Clinical and Molecular Parasitology, National Liver Institute, Menoufia University, Menoufia, Egypt., Selim SM; Department of Clinical and Molecular Parasitology, National Liver Institute, Menoufia University, Menoufia, Egypt., Sharaf SA; Department of Clinical and Molecular Parasitology, National Liver Institute, Menoufia University, Menoufia, Egypt., Mohsen KK; Department of Clinical and Molecular Parasitology, National Liver Institute, Menoufia University, Menoufia, Egypt. drkhloud.kamel@liver.menofia.edu.eg., Allam DM; Department of Pathology, Faculty of Medicine, Menoufia University, Shibin Elkom, Egypt., Elkhadry SW; Department of Epidemiology and Preventive Medicine, National Liver Institute, Menoufia University, Menoufia, Egypt., Gouda MA; Department of Clinical and Molecular Parasitology, National Liver Institute, Menoufia University, Menoufia, Egypt.
Jazyk: angličtina
Zdroj: Parasitology research [Parasitol Res] 2024 Jul 24; Vol. 123 (7), pp. 286. Date of Electronic Publication: 2024 Jul 24.
DOI: 10.1007/s00436-024-08280-4
Abstrakt: Despite being the initial choice for treating toxoplasmosis, sulfadiazine and pyrimethamine have limited effectiveness in eliminating the infection and were linked to a variety of adverse effects. Therefore, the search for new effective therapeutic strategies against toxoplasmosis is still required. The current work is the first research to assess the efficacy of spiramycin-loaded maltodextrin nanoparticles (SPM-loaded MNPs) as a novel alternative drug therapy against toxoplasmosis in a murine model. Fifty laboratory-bred Swiss albino mice were divided into five groups: normal control group (GI, n = 10), positive control group (GII, n = 10), orally treated with spiramycin (SPM) alone (GIII, n = 10), intranasal treated with SPM-loaded MNPs (GIV, n = 10), and orally treated with SPM-loaded MNPs (GV, n = 10). Cysts of Toxoplasma gondii ME-49 strain were used to infect the mice. Tested drugs were administered 2 months after the infection. Drug efficacy was assessed by counting brain cysts, histopathological examination, and measures of serum CD19 by flow cytometer. The orally treated group with SPM-loaded MNPs (GV) showed a marked reduction of brain cyst count (88.7%), histopathological improvement changes, and an increasing mean level of CD19 (80.2%) with significant differences. SPM-loaded MNPs showed potent therapeutic effects against chronic toxoplasmosis. Further research should be conducted to assess it in the treatment of human toxoplasmosis, especially during pregnancy.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz: